Skip to content
Review

Conformational allocation of mitofusin 2 in neuronal mitochondrial dynamics: Mechanisms and therapeutic targeting.

Oct 2026 · Biochemical Pharmacology · pp. 118545 · 0 citations · 110 references
Medicine

TL;DR

This work proposes a testable conformational-allocation framework in which molecular state distributions and transition kinetics bias MFN2 participation across cellular outputs, and provides the strongest context for intervention, combining causal genetics, direct mitofusin engagement studies, and multiscale rescue.

Abstract

Neurons must sustain functional mitochondria far from the cell body. Mitofusin 2 (MFN2), a dynamin-like large guanosine triphosphatase (GTPase), coordinates outer mitochondrial membrane remodeling with axonal transport, bioenergetic support, inter-organelle communication, and stress-responsive quality control. Studying these activities separately obscures how disruption of one protein produces diverse neuronal phenotypes. We propose a testable conformational-allocation framework in which molecular state distributions and transition kinetics bias MFN2 participation across cellular outputs. Integrating structural and functional evidence, we distinguish experimentally resolved mechanisms from working models. Variants associated with Charcot-Marie-Tooth disease type 2A (CMT2A) are compared by the molecular step or functional output affected. Fusion loss alone does not capture this mechanistic diversity. Structure-guided docking supports local compatibility at a shallow, conformationally conditional C-terminal surface, without establishing native accessibility, affinity, or therapeutic response. CMT2A provides the strongest context for intervention, combining causal genetics, direct mitofusin engagement studies, and multiscale rescue. Amyotrophic lateral sclerosis (ALS) provides secondary preclinical evidence, whereas Alzheimer's and Parkinson's diseases remain exploratory. The mitofusin pathway is chemically tractable, but paralog selectivity and state-dependent target engagement remain unresolved. A state- and variant-informed strategy may better match intervention to the affected output than indiscriminate enhancement of fusion.

View source

Similar papers

Review 2025

An exquisite symphony: protein post-translational modifications govern mitochondrial fate

Ten key PTMs, including lactylation, succinylation, succinylation, SUMOylation, and S-nitrosylation, acting on core regulators such as dynamin-related protein 1(DRP1), optic atrophy 1 (OPA1), Parkin, and mitochondrial Rho GTPase 1 (MIRO1) are summarized to provide a comprehensive resource for understanding mitochondria...

Haolin Ding, E. Taoxia, Jing-Cai He et al. · 0 citations
Open access Sep 2026

Disrupting Mitochondrial Homeostasis via TBC1D15 Protein

This work resolves the long-standing ambiguity between TBC1D15 total expression level and its subcellular shuttling, establishing a new conceptual framework that prioritizes protein translocation over bulk abundance in organelle quality control.

Peng-Fei Qiang, Yan Li, Shuang Liang et al. · 0 citations
Review Sep 2026

Deubiquitinases in mitophagy: therapeutic control of mitochondrial quality.

Current understanding of mitochondrial DUBs in physiology and disease is synthesized and emerging pharmacological strategies to guide the development of mitophagy-targeted therapeutics are discussed.

Yang Xu, Bahareh Behrouz, Andrew Lee et al. · 0 citations
Editorial Open access Sep 2026

Mitochondrial Crossroads in Neurobiology: From Cellular Vulnerability to Therapeutic Opportunity

Overall, this Collection positions mitochondrial biology as a mechanistic framework connecting metabolic dysfunction, cellular stress, neuroinflammation, and neuronal degeneration, and supports its development as a therapeutic target for disease-modifying interventions in neurological disorders.

Rita Valenzuela, A. I. Rodriguez-Perez · 0 citations
Review Open access Sep 2026

Mitophagy as an active regulator of cardiac metabolic reprogramming

This review critically assess the AMP-activated protein kinase (AMPK)–UNC-51-like kinase 1 (ULK1), sirtuin 3 (SIRT3)–peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), PTEN-induced kinase 1 (PINK1)–Parkin E3 ubiquitin ligase, and hypoxia-inducible factor 1-alpha

Li-Zheng Gai, Yan Li, Chen Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.